

David J Brayden

List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/6597857/publications.pdf](https://exaly.com/author-pdf/6597857/publications.pdf)

Version: 2024-02-01

151
papers

6,856
citations

53202

45
h-index

70222

77
g-index

155
all docs

155
docs citations

155
times ranked

7995
citing authors

#	ARTICLE	IF	CITATIONS
1	Reproducible Synthesis of Biocompatible Albumin Nanoparticles Designed for Intra-articular Administration of Celecoxib to Treat Osteoarthritis. <i>ACS Applied Materials & Interfaces</i> , 2024, 16, 14633-14644.	8.3	0
2	Labrafac TM MC60 is an efficacious intestinal permeation enhancer for macromolecules: Comparisons with Labrasol [®] ALF in ex vivo and in vivo rat studies. <i>International Journal of Pharmaceutics</i> , 2024, 661, 124353.	5.4	0
3	Evaluation of Selenomethionine Entrapped in Nanoparticles for Oral Supplementation Using In Vitro, Ex Vivo and In Vivo Models. <i>Molecules</i> , 2023, 28, 2941.	3.9	0
4	Best practices in current models mimicking drug permeability in the gastrointestinal tract - An UNGAP review. <i>European Journal of Pharmaceutical Sciences</i> , 2022, 170, 106098.	4.1	33
5	Impact of PEGylation on an antibody-loaded nanoparticle-based drug delivery system for the treatment of inflammatory bowel disease. <i>Acta Biomaterialia</i> , 2022, 140, 561-572.	8.8	17
6	Add Sugar to Chitosan: Mucoadhesion and In Vitro Intestinal Permeability of Mannosylated Chitosan Nanocarriers. <i>Pharmaceutics</i> , 2022, 14, 830.	4.6	7
7	A Critical Overview of the Biological Effects of Excipients (Part II): Scientific Considerations and Tools for Oral Product Development. <i>AAPS Journal</i> , 2022, 24, 61.	4.7	2
8	Barriers to the Intestinal Absorption of Four Insulin-Loaded Arginine-Rich Nanoparticles in Human and Rat. <i>ACS Nano</i> , 2022, 16, 14210-14229.	15.3	11
9	Formulation, Characterisation and Evaluation of the Antihypertensive Peptides, Isoleucine-Proline-Proline and Leucine-Lysine-Proline in Chitosan Nanoparticles Coated with Zein for Oral Drug Delivery. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11160.	4.2	12
10	Localised Delivery of Macromolecules to the Large Intestine: Translation to Clinical Trials. <i>BioDrugs</i> , 2022, 36, 687-700.	5.0	3
11	Per Artursson's Major Contributions to the Caco-2 Cell Literature in Pharmaceutical Sciences. <i>Journal of Pharmaceutical Sciences</i> , 2021, 110, 12-16.	3.3	2
12	Addressing the challenges to increase the efficiency of translating nanomedicine formulations to patients. <i>Expert Opinion on Drug Discovery</i> , 2021, 16, 235-254.	5.1	9
13	Intestinal permeation enhancers to improve oral bioavailability of macromolecules: reasons for low efficacy in humans. <i>Expert Opinion on Drug Delivery</i> , 2021, 18, 273-300.	5.1	40
14	Comparison of the effects of the intestinal permeation enhancers, SNAC and sodium caprate (C10): Isolated rat intestinal mucosae and sacs. <i>European Journal of Pharmaceutical Sciences</i> , 2021, 158, 105685.	4.1	26
15	Sodium glycodeoxycholate and sodium deoxycholate as epithelial permeation enhancers: in vitro and ex vivo intestinal and buccal bioassays. <i>European Journal of Pharmaceutical Sciences</i> , 2021, 159, 105737.	4.1	17
16	Protein kinase D, ubiquitin and proteasome pathways are involved in adenosine receptor-stimulated NR4A expression in myeloid cells. <i>Biochemical and Biophysical Research Communications</i> , 2021, 555, 19-25.	2.2	2
17	Permeability-enhancing effects of three laurate-disaccharide monoesters across isolated rat intestinal mucosae. <i>International Journal of Pharmaceutics</i> , 2021, 601, 120593.	5.4	9
18	Synthesis and In Vivo Evaluation of Insulin-Loaded Whey Beads as an Oral Peptide Delivery System. <i>Pharmaceutics</i> , 2021, 13, 656.	4.6	4

#	ARTICLE	IF	CITATIONS
19	Transient Permeation Enhancer [®] (TPE [®]) technology for oral delivery of octreotide: a technological evaluation. <i>Expert Opinion on Drug Delivery</i> , 2021, 18, 1501-1512.	5.1	45
20	Entrapment of Hydrophilic and Hydrophobic Molecules in Beads Prepared from Isolated Denatured Whey Protein. <i>Pharmaceutics</i> , 2021, 13, 1001.	4.6	2
21	The Centenary of the Discovery of Insulin: An Update on the Quest for Oral Delivery. <i>Frontiers in Drug Delivery</i> , 2021, 1, .	1.7	14
22	Formulation strategies to improve the efficacy of intestinal permeation enhancers,. <i>Advanced Drug Delivery Reviews</i> , 2021, 177, 113925.	14.3	47
23	Measuring the oral bioavailability of protein hydrolysates derived from food sources: A critical review of current bioassays. <i>Biomedicine and Pharmacotherapy</i> , 2021, 144, 112275.	5.8	11
24	Drug Delivery Formulations and Devices Tailored for Paediatric and Older Patients. <i>Frontiers in Drug Delivery</i> , 2021, 1, .	1.7	0
25	Silica-Coated Nanoparticles with a Core of Zinc, Arginine, and a Peptide Designed for Oral Delivery. <i>ACS Applied Materials & Interfaces</i> , 2020, 12, 1257-1269.	8.3	29
26	Salcaprozate sodium (SNAC) enhances permeability of octreotide across isolated rat and human intestinal epithelial mucosae in Ussing chambers. <i>European Journal of Pharmaceutical Sciences</i> , 2020, 154, 105509.	4.1	28
27	A head-to-head Caco-2 assay comparison of the mechanisms of action of the intestinal permeation enhancers: SNAC and sodium caprate (C10). <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2020, 152, 95-107.	4.4	42
28	Evolving peptides for oral intake. <i>Nature Biomedical Engineering</i> , 2020, 4, 487-488.	22.4	7
29	An Enteric-Coated Polyelectrolyte Nanocomplex Delivers Insulin in Rat Intestinal Instillations When Combined with a Permeation Enhancer. <i>Pharmaceutics</i> , 2020, 12, 259.	4.6	18
30	Amphiphilic Star Polypept(o)ides as Nanomeric Vectors in Mucosal Drug Delivery. <i>Biomacromolecules</i> , 2020, 21, 2455-2462.	5.6	19
31	Labrasol [®] is an efficacious intestinal permeation enhancer across rat intestine: Ex vivo and in vivo rat studies. <i>Journal of Controlled Release</i> , 2019, 310, 115-126.	10.2	81
32	Evaluation of Sucrose Laurate as an Intestinal Permeation Enhancer for Macromolecules: Ex Vivo and In Vivo Studies. <i>Pharmaceutics</i> , 2019, 11, 565.	4.6	38
33	Application of Permeation Enhancers in Oral Delivery of Macromolecules: An Update. <i>Pharmaceutics</i> , 2019, 11, 41.	4.6	119
34	Stomaching Drug Delivery. <i>New England Journal of Medicine</i> , 2019, 380, 1671-1673.	30.1	7
35	Intestinal Permeation Enhancers for Oral Delivery of Macromolecules: A Comparison between Salcaprozate Sodium (SNAC) and Sodium Caprate (C10). <i>Pharmaceutics</i> , 2019, 11, 78.	4.6	149
36	Effect of Overencapsulation on the Disintegration and Dissolution of Licensed Formulations for Blinding in Randomized Controlled Trials. <i>Journal of Pharmaceutical Sciences</i> , 2019, 108, 1227-1235.	3.3	3

#	ARTICLE	IF	CITATIONS
37	Labrasol® and Salts of Medium-Chain Fatty Acids Can Be Combined in Low Concentrations to Increase the Permeability of a Macromolecule Marker Across Isolated Rat Intestinal Mucosae. <i>Journal of Pharmaceutical Sciences</i> , 2018, 107, 1648-1655.	3.3	18
38	Effects of surfactant-based permeation enhancers on mannitol permeability, histology, and electrogenic ion transport responses in excised rat colonic mucosae. <i>International Journal of Pharmaceutics</i> , 2018, 539, 11-22.	5.4	39
39	Track Analysis of the Passage of rhodamine-labeled Liposomes Across Porcine Jejunal Mucus in a Microchannel Device. <i>Therapeutic Delivery</i> , 2018, 9, 419-433.	2.5	9
40	Sodium caprate enables the blood pressure-lowering effect of Ile-Pro-Pro and Leu-Lys-Pro in spontaneously hypertensive rats by indirectly overcoming PepT1 inhibition. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2018, 128, 179-187.	4.4	24
41	TNF \pm -dependent anhedonia and upregulation of hippocampal serotonin transporter activity in a mouse model of collagen-induced arthritis. <i>Neuropharmacology</i> , 2018, 137, 211-220.	4.2	12
42	Intra-articular delivery of a nanocomplex comprising salmon calcitonin, hyaluronic acid, and chitosan using an equine model of joint inflammation. <i>Drug Delivery and Translational Research</i> , 2018, 8, 1421-1435.	6.0	14
43	Physicochemical, pharmacokinetic and pharmacodynamic analyses of amphiphilic cyclodextrin-based nanoparticles designed to enhance intestinal delivery of insulin. <i>Journal of Controlled Release</i> , 2018, 286, 402-414.	10.2	49
44	Evaluation of PepT1 transport of food-derived antihypertensive peptides, Ile-Pro-Pro and Leu-Lys-Pro using in vitro, ex vivo and in vivo transport models. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2017, 115, 276-284.	4.4	42
45	Nanoparticle passage through porcine jejunal mucus: Microfluidics and rheology. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2017, 13, 863-873.	3.5	36
46	Progress in the Formulation and Delivery of Somatostatin Analogs for Acromegaly. <i>Therapeutic Delivery</i> , 2017, 8, 867-878.	2.5	14
47	A comparison of three Peyer's patch α M-like cell culture models: particle uptake, bacterial interaction, and epithelial histology. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2017, 119, 426-436.	4.4	25
48	Buccal delivery of small molecules and biologics: of mucoadhesive polymers, films, and nanoparticles. <i>Current Opinion in Pharmacology</i> , 2017, 36, 22-28.	3.6	69
49	Development of a Non-Aqueous Dispersion to Improve Intestinal Epithelial Flux of Poorly Permeable Macromolecules. <i>AAPS Journal</i> , 2017, 19, 244-253.	4.7	6
50	Editorial overview: New technologies: drug delivery and medical devices combinations, more than the sum of the parts. <i>Current Opinion in Pharmacology</i> , 2017, 36, iv-vii.	3.6	0
51	Safety concerns over the use of intestinal permeation enhancers: A mini-review. <i>Tissue Barriers</i> , 2016, 4, e1176822.	3.2	104
52	Oral delivery strategies for nutraceuticals: Delivery vehicles and absorption enhancers. <i>Trends in Food Science and Technology</i> , 2016, 53, 90-101.	15.7	96
53	Coated minispheres of salmon calcitonin target rat intestinal regions to achieve systemic bioavailability: Comparison between intestinal instillation and oral gavage. <i>Journal of Controlled Release</i> , 2016, 238, 242-252.	10.2	17
54	Oral delivery of peptides: opportunities and issues for translation. <i>Advanced Drug Delivery Reviews</i> , 2016, 106, 193-195.	14.3	51

#	ARTICLE	IF	CITATIONS
55	The Challenges and Future of Oral Drug Delivery: An Interview with David Brayden. <i>Therapeutic Delivery</i> , 2016, 7, 791-794.	2.5	0
56	Introduction for the special issue on recent advances in drug delivery across tissue barriers. <i>Tissue Barriers</i> , 2016, 4, e1187981.	3.2	3
57	Intestinal permeation enhancers for oral peptide delivery. <i>Advanced Drug Delivery Reviews</i> , 2016, 106, 277-319.	14.3	275
58	Hepatic gateways. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 561-563.	3.0	0
59	Stability, toxicity and intestinal permeation enhancement of two food-derived antihypertensive tripeptides, Ile-Pro-Pro and Leu-Lys-Pro. <i>Peptides</i> , 2015, 71, 1-7.	2.4	37
60	Development of Nanotoxicology: Implications for Drug Delivery and Medical Devices. <i>Nanomedicine</i> , 2015, 10, 2289-2305.	3.5	13
61	High-content analysis for drug delivery and nanoparticle applications. <i>Drug Discovery Today</i> , 2015, 20, 942-957.	6.6	41
62	In vitro and in vivo preclinical evaluation of a minisphere emulsion-based formulation (SmPill [®]) of salmon calcitonin. <i>European Journal of Pharmaceutical Sciences</i> , 2015, 79, 102-111.	4.1	23
63	Sodium caprate-induced increases in intestinal permeability and epithelial damage are prevented by misoprostol. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2015, 94, 194-206.	4.4	40
64	First-in-class thyrotropin-releasing hormone (TRH)-based compound binds to a pharmacologically distinct TRH receptor subtype in human brain and is effective in neurodegenerative models. <i>Neuropharmacology</i> , 2015, 89, 193-203.	4.2	19
65	Investigation of coco-glucoside as a novel intestinal permeation enhancer in rat models. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2014, 88, 856-865.	4.4	29
66	A head-to-head multi-parametric high content analysis of a series of medium chain fatty acid intestinal permeation enhancers in Caco-2 cells. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2014, 88, 830-839.	4.4	68
67	Redox-Mediated Angiogenesis in the Hypoxic Joint of Inflammatory Arthritis. <i>Arthritis and Rheumatology</i> , 2014, 66, 3300-3310.	6.8	42
68	Progress in the delivery of nanoparticle constructs: towards clinical translation. <i>Current Opinion in Pharmacology</i> , 2014, 18, 120-128.	3.6	43
69	Translocation of <i>Vibrio parahaemolyticus</i> across an in vitro M cell model. <i>FEMS Microbiology Letters</i> , 2014, 350, 65-71.	1.8	11
70	Formulation Strategies to Improve Oral Peptide Delivery. <i>Pharmaceutical Patent Analyst</i> , 2014, 3, 313-336.	0.7	58
71	Efficacious Intestinal Permeation Enhancement Induced by the Sodium Salt of 10-undecylenic Acid, A Medium Chain Fatty Acid Derivative. <i>AAPS Journal</i> , 2014, 16, 1064-1076.	4.7	29
72	Transepithelial Transport of PAMAM Dendrimers across Isolated Rat Jejunal Mucosae in Ussing Chambers. <i>Biomacromolecules</i> , 2014, 15, 2889-2895.	5.6	14

#	ARTICLE	IF	CITATIONS
73	The role of citric acid in oral peptide and protein formulations: Relationship between calcium chelation and proteolysis inhibition. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2014, 86, 544-551.	4.4	63
74	Poly(Ethylene Glycol)-Based Backbones with High Peptide Loading Capacities. <i>Molecules</i> , 2014, 19, 17559-17577.	3.9	9
75	Human: Veterinary Technology Cross Over. <i>Advances in Delivery Science and Technology</i> , 2013, , 359-375.	0.0	0
76	Colonic absorption of salmon calcitonin using tetradecyl maltoside (TDM) as a permeation enhancer. <i>European Journal of Pharmaceutical Sciences</i> , 2013, 48, 726-734.	4.1	23
77	An intra-articular salmon calcitonin-based nanocomplex reduces experimental inflammatory arthritis. <i>Journal of Controlled Release</i> , 2013, 167, 120-129.	10.2	61
78	Drug delivery to inflamed colon by nanoparticles: Comparison of different strategies. <i>International Journal of Pharmaceutics</i> , 2013, 440, 3-12.	5.4	155
79	Opportunities for drug-delivery Research in Nutraceuticals and Functional foods?. <i>Therapeutic Delivery</i> , 2013, 4, 301-305.	2.5	6
80	Direct Peptide Bioconjugation/PEGylation at Tyrosine with Linear and Branched Polymeric Diazonium Salts. <i>Journal of the American Chemical Society</i> , 2012, 134, 7406-7413.	14.6	129
81	Evaluation of alkylmaltosides as intestinal permeation enhancers: Comparison between rat intestinal mucosal sheets and Caco-2 monolayers. <i>European Journal of Pharmaceutical Sciences</i> , 2012, 47, 701-712.	4.1	48
82	Overcoming poor permeability: translating permeation enhancers for oral peptide delivery. <i>Drug Discovery Today: Technologies</i> , 2012, 9, e113-e119.	4.2	78
83	Zinc sulphate attenuates chloride secretion in Human colonic mucosae in vitro. <i>European Journal of Pharmacology</i> , 2012, 696, 166-171.	3.6	14
84	Mechanisms of action of zinc on rat intestinal epithelial electrogenic ion secretion: insights into its antidiarrhoeal actions. <i>Journal of Pharmacy and Pharmacology</i> , 2012, 64, 644-653.	2.6	16
85	Nanostructures Overcoming the Intestinal Barrier: Physiological Considerations and Mechanistic Issues. , 2012, , 39-62.		4
86	NANOSTRUCTURES OVERCOMING THE INTESTINAL BARRIER: DRUG DELIVERY STRATEGIES. , 2012, , 63-90.		3
87	Oral delivery of macromolecules: rationale underpinning Gastrointestinal Permeation Enhancement Technology (GIPET [®]). <i>Therapeutic Delivery</i> , 2011, 2, 1595-1610.	2.5	65
88	High content analysis to determine cytotoxicity of the antimicrobial peptide, melittin and selected structural analogs. <i>Peptides</i> , 2011, 32, 1764-1773.	2.4	25
89	Oral Peptide Delivery: Prioritizing the Leading Technologies. <i>Therapeutic Delivery</i> , 2011, 2, 1567-1573.	2.5	29
90	PK/PD modelling of comb-shaped PEGylated salmon calcitonin conjugates of differing molecular weights. <i>Journal of Controlled Release</i> , 2011, 149, 126-132.	10.2	25

#	ARTICLE	IF	CITATIONS
91	Resistance of Staphylococcus aureus to the cationic antimicrobial agent poly(2-(dimethylamino) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf Medical Microbiology, 2011, 60, 968-976.	1.8	48
92	Conference Report: the 2nd Annual Irish Drug Delivery Network Conference With UK and Ireland Controlled Release Society: Advancing Drug Delivery. Therapeutic Delivery, 2010, 1, 505-509.	2.5	0
93	Restoration of Rat Colonic Epithelium After <i>In Situ</i> Intestinal Instillation of the Absorption promoter, Sodium Caprate. Therapeutic Delivery, 2010, 1, 75-82.	2.5	45
94	High content analysis of cytotoxic effects of pDMAEMA on human intestinal epithelial and monocyte cultures. Journal of Controlled Release, 2010, 146, 84-92.	10.2	54
95	In vitro and in vivo characterisation of a novel peptide delivery system: Amphiphilic polyelectrolyteâ€“salmon calcitonin nanocomplexes. Journal of Controlled Release, 2010, 147, 289-297.	10.2	40
96	Impact of amino acid replacements on in vitro permeation enhancement and cytotoxicity of the intestinal absorption promoter, melittin. International Journal of Pharmaceutics, 2010, 387, 154-160.	5.4	27
97	Drug Delivery Systems in Domestic Animal Species. Handbook of Experimental Pharmacology, 2010, , 79-112.	0.0	18
98	Oral Absorption Enhancement: Taking the Next Steps in Therapeutic Delivery. Therapeutic Delivery, 2010, 1, 5-9.	2.5	8
99	Antibacterial Effects of Poly(2-(dimethylamino ethyl)methacrylate) against Selected Gram-Positive and Gram-Negative Bacteria. Biomacromolecules, 2010, 11, 443-453.	5.6	211
100	Controlled Release Drug Delivery in Farmed Animals: Commercial Challenges and Academic Opportunities. Current Drug Delivery, 2009, 6, 383-390.	1.7	15
101	Dexamethasoneâ€“pDMAEMA polymeric conjugates reduce inflammatory biomarkers in human intestinal epithelial monolayers. Journal of Controlled Release, 2009, 135, 35-43.	10.2	47
102	Conjugation of salmon calcitonin to a combed-shaped end functionalized poly(poly(ethylene glycol)) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 135, 51-59.	10.2	78
103	Evaluation of intestinal absorption and mucosal toxicity using two promoters. II. Rat instillation and perfusion studies. European Journal of Pharmaceutical Sciences, 2009, 38, 301-311.	4.1	32
104	Evaluation of intestinal absorption enhancement and local mucosal toxicity of two promoters. I. Studies in isolated rat and human colonic mucosae. European Journal of Pharmaceutical Sciences, 2009, 38, 291-300.	4.1	48
105	Site-specific N-terminus conjugation of poly(mPEG1100) methacrylates to salmon calcitonin: synthesis and preliminary biological evaluation. Soft Matter, 2009, 5, 3038.	2.8	26
106	Safety and efficacy of sodium caprate in promoting oral drug absorption: from in vitro to the clinic. Advanced Drug Delivery Reviews, 2009, 61, 1427-1449.	14.3	199
107	Phosphine-mediated one-pot thiolâ€“ene â€œclickâ€“approach to polymerâ€“protein conjugates. Chemical Communications, 2009, , 5272.	4.2	111
108	In vitro Interactions Between the Oral Absorption Promoter, Sodium Caprate (C10) and S. typhimurium in Rat Intestinal Ileal Mucosae. Pharmaceutical Research, 2008, 25, 114-122.	3.6	22

#	ARTICLE	IF	CITATIONS
109	A Tertiary Amino-Containing Polymethacrylate Polymer Protects Mucus-Covered Intestinal Epithelial Monolayers Against Pathogenic Challenge. <i>Pharmaceutical Research</i> , 2008, 25, 1193-1201.	3.6	16
110	Myosin Light Chain Kinase Inhibition: Correction of Increased Intestinal Epithelial Permeability In Vitro. <i>Pharmaceutical Research</i> , 2008, 25, 1377-1386.	3.6	64
111	Avermectin transepithelial transport in MDR1- and MRP-transfected canine kidney monolayers. <i>Veterinary Research Communications</i> , 2008, 32, 93-106.	1.6	38
112	Effects of <i>Lactobacillus salivarius</i> 433118 on Intestinal Inflammation, Immunity Status and In Vitro Colon Function in Two Mouse Models of Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2008, 53, 2495-2506.	2.4	40
113	Feline immunodeficiency virus infection: A valuable model to study HIV-1 associated encephalitis. <i>Veterinary Immunology and Immunopathology</i> , 2008, 123, 134-137.	1.2	11
114	Increased Intestinal Permeability in Rats Subjected to Traumatic Frontal Lobe Percussion Brain Injury. <i>Journal of Trauma</i> , 2008, 64, 131-138.	2.2	45
115	Cracking the Junction: Update on the Progress of Gastrointestinal Absorption Enhancement in the Delivery of Poorly Absorbed Drugs. <i>Critical Reviews in Therapeutic Drug Carrier Systems</i> , 2008, 25, 117-168.	2.5	47
116	Melittin as a Permeability Enhancer II: In Vitro Investigations in Human Mucus Secreting Intestinal Monolayers and Rat Colonic Mucosae. <i>Pharmaceutical Research</i> , 2007, 24, 1346-1356.	3.6	31
117	Melittin as an Epithelial Permeability Enhancer I: Investigation of Its Mechanism of Action in Caco-2 Monolayers. <i>Pharmaceutical Research</i> , 2007, 24, 1336-1345.	3.6	35
118	Promoting absorption of drugs in humans using medium-chain fatty acid-based solid dosage forms: GIPET. <i>Expert Opinion on Drug Delivery</i> , 2006, 3, 685-692.	5.1	110
119	New technologies Pharmacology applied: delivering the goods. <i>Current Opinion in Pharmacology</i> , 2006, 6, 491-493.	3.6	0
120	Growth and characterisation of a cell culture model of the feline blood-brain barrier. <i>Veterinary Immunology and Immunopathology</i> , 2006, 109, 233-244.	1.2	22
121	Fluorescently tagged star polymers by living radical polymerisation for mucoadhesion and bioadhesion. <i>Reactive and Functional Polymers</i> , 2006, 66, 51-64.	4.3	59
122	Rat, ovine and bovine Peyer's patches mounted in horizontal diffusion chambers display sampling function. <i>Journal of Controlled Release</i> , 2006, 115, 68-77.	10.2	21
123	Keynote review: Intestinal Peyer's patch M cells and oral vaccine targeting. <i>Drug Discovery Today</i> , 2005, 10, 1145-1157.	6.6	205
124	Targeting antigens to murine and human M-cells with <i>Aleuria aurantia</i> lectin-functionalized microparticles. <i>Immunology Letters</i> , 2005, 100, 182-188.	2.7	43
125	In Vitro and ex Vivo Intestinal Tissue Models to Measure Mucoadhesion of Poly (Methacrylate) and N-Trimethylated Chitosan Polymers. <i>Pharmaceutical Research</i> , 2005, 22, 38-49.	3.6	92
126	Cell culture modeling of specialized tissue: identification of genes expressed specifically by follicle-associated epithelium of Peyer's patch by expression profiling of Caco-2/Raji co-cultures. <i>International Immunology</i> , 2004, 16, 91-99.	4.0	79

#	ARTICLE	IF	CITATIONS
127	Pathogen invasion across intestine: mechanisms and potential exploitation. <i>Advanced Drug Delivery Reviews</i> , 2004, 56, 717-719.	14.3	0
128	Apical membrane receptors on intestinal M cells: potential targets for vaccine delivery. <i>Advanced Drug Delivery Reviews</i> , 2004, 56, 721-726.	14.3	43
129	Oral Delivery of Pathogens from the Intestine to the Nervous System. <i>Journal of Drug Targeting</i> , 2004, 12, 71-78.	4.5	6
130	Controlled release technologies for drug delivery. <i>Drug Discovery Today</i> , 2003, 8, 976-978.	6.6	81
131	Peptidoglycan recognition protein expression in mouse Peyer's Patch follicle associated epithelium suggests functional specialization. <i>Cellular Immunology</i> , 2003, 224, 8-16.	3.0	68
132	In vitro inhibition of cytochalasin induced tight junction opening in human colon. <i>Gastroenterology</i> , 2003, 124, A316.	1.4	0
133	Catching target receptors for drug and vaccine delivery using TOGA® gene expression profiling. <i>Advanced Drug Delivery Reviews</i> , 2002, 54, 1213-1223.	14.3	11
134	Protection against <i>Bordetella pertussis</i> infection following parenteral or oral immunization with antigens entrapped in biodegradable particles: effect of formulation and route of immunization on induction of Th1 and Th2 cells. <i>Vaccine</i> , 2001, 19, 1940-1950.	4.0	116
135	Encapsulation in biodegradable microparticles enhances serum antibody response to parenterally-delivered I ² -amyloid in mice. <i>Vaccine</i> , 2001, 19, 4185-4193.	4.0	22
136	Targeting polymerised liposome vaccine carriers to intestinal M cells. <i>Vaccine</i> , 2001, 20, 208-217.	4.0	117
137	<i>In Vitro</i> Models of the Intestinal Barrier. <i>ATLA Alternatives To Laboratory Animals</i> , 2001, 29, 649-668.	1.4	197
138	Microparticle vaccine approaches to stimulate mucosal immunisation. <i>Microbes and Infection</i> , 2001, 3, 867-876.	2.0	63
139	Oral vaccination in man using antigens in particles: current status. <i>European Journal of Pharmaceutical Sciences</i> , 2001, 14, 183-189.	4.1	75
140	Iontophoresis-enhanced absorptive flux of polar molecules across intestinal tissue in vitro. <i>Pharmaceutical Research</i> , 2000, 17, 476-478.	3.6	13
141	Evaluation of the Caco-2 monolayer as a model epithelium for iontophoretic transport. <i>Pharmaceutical Research</i> , 2000, 17, 1181-1188.	3.6	39
142	Expression of Specific Markers and Particle Transport in a New Human Intestinal M-Cell Model. <i>Biochemical and Biophysical Research Communications</i> , 2000, 279, 808-813.	2.2	249
143	Fast-track approaches to selecting discovery candidates for full development. <i>Drug Discovery Today</i> , 1998, 3, 6-7.	6.6	0
144	Binding and uptake of biodegradable poly-dl-lactide micro- and nanoparticles in intestinal epithelia. <i>European Journal of Pharmaceutical Sciences</i> , 1998, 6, 153-163.	4.1	251

#	ARTICLE	IF	CITATIONS
145	Novel oral drug delivery gateways for biotechnology products: polypeptides and vaccines. <i>Pharmaceutical Science & Technology Today</i> , 1998, 1, 291-299.	0.9	33
146	Non-antibiotic anti-diarrhoeal drugs: factors affecting oral bioavailability of berberine and loperamide in intestinal tissue. <i>Advanced Drug Delivery Reviews</i> , 1997, 23, 111-120.	14.3	47
147	A novel in vitro electrophysiological bioassay for transport of loperamide across intestinal epithelia. <i>Pharmaceutical Research</i> , 1997, 14, 942-945.	3.6	3
148	Heparin absorption across the intestine: effects of sodium N-[8-(2-hydroxybenzoyl)amino]caprylate in rat in situ intestinal instillations and in Caco-2 monolayers. <i>Pharmaceutical Research</i> , 1997, 14, 1772-1779.	3.6	68
149	Cultured human sweat gland epithelia: isolation of glands using neutral red. <i>Pharmaceutical Research</i> , 1995, 12, 171-175.	3.6	16
150	AB069. NR4A1 agonist CsnB may affect macrophage cells primarily within colorectal tumours in order to reduce pro-inflammatory response. <i>Mesentery and Peritoneum</i> , 0, 4, AB069-AB069.	0.1	0
151	AB073. Attenuation of pathogenic pro-inflammatory signals in colorectal cancer via an NR4A1 agonist cytosporone B. <i>Mesentery and Peritoneum</i> , 0, 4, AB073-AB073.	0.1	0